[Intracoronary brachytherapy--an update].
Restenosis following angioplasty represents a major clinical problem in the field of percutaneous coronary interventions. Intravascular brachytherapy reduces risk of restenosis following percutaneous interventions of native lesions and in-stent restenosis up to 50%-60%. This effect can be shown for at least one to two years. This novel therapeutic strategy is limited by a higher rate of target vessel reinterventions, and late coronary thrombosis, when platelet inhibiting drugs has been withdrawn or after implantation of multiple stents. Currently, intracoronary brachytherapy is mainly considered for treatment of in-stent-restenosis.
Auer
J
J
II. Interne Abteilung mit Kardiologie und Internistische Intensivmedizin, Allgemeines Krankenhaus Wels, Grieskirchnerstrasse 42, A-4600 Wels. johann.auer@khwels.at
Berent
R
R
Punzengruber
C
C
Maurer
E
E
Lassnig
E
E
Weber
T
T
Eber
B
B
D015906:Angioplasty, Balloon, Coronary; D001918:Brachytherapy / Q000295:instrumentation; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000532:radiotherapy*; D023903:Coronary Restenosis / Q000532:radiotherapy*; D004867:Equipment Design; D006801:Humans; D015607:Stents